13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • Combi-A Plus

    Acronym: 

    Combi-A Plus

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Melanoma & other skin
    Trial Type Treatment
    Phase Phase III Tumour Stream Melanoma
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Melanoma & other skin
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Melanoma
    Cancer Stage All stages
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    Open-label, phase IIIb study of dabrafenib in combination with tametinib in the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma after complete resection to evaluate the impact on pyrexia related outcomes of an adapted pyrexia AE- management algorithm. Key inclusion criteria: completely resected stage IIIA, IIIB, IIIC, IIID - no more than 12 weeks before enrolement, V600E/K, No uveal or mucosal melanoma, no prior adjuvant treatment.

    Lay Summary

    Sponsor / Cooperative group

    Novartis

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Completed